Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06460493
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-06-10
Brief Title:
Effect of Ensifentrine Treatment on CAT Score
Sponsor:
Verona Pharma plc
Organization:
Verona Pharma plc
Study Overview
Official Title:
A Study Assessing the Effect of Ensifentrine on CAT Scores Over 12 Weeks in Subjects With Moderate to Severe COPD
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label study at one study center that will assess the effect of twice-daily nebulized ensifentrine on COPD Assessment Test CAT scores over 12 weeks in subjects with moderate to severe COPD Subjects will continue their long-acting dual or triple COPD maintenance treatments during study participation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None